Citizen Petition from Alliance to Protect Insulin Choice

The commenter, a long-term Type 1 Diabetes patient, supports the petition by expressing frustration over the high costs and poor efficacy of current insulin options compared to older, more affordable products. They specifically request the return of Levemir and a resolution to the pricing issues caused by insulin manufacturers.

An individual with type 1 diabetes shares their personal struggle with insulin types and medical complications. They express a desire for more choice in insulin options to manage their health effectively.

A patient who relies on Levemir (insulin detemir) for metabolic stability argues that the drug is not interchangeable with other basal insulins due to its unique pharmacokinetic profile. They urge the FDA to designate Levemir as a drug in shortage to ensure continued manufacturing and prevent a decline in patient care.

Sydney Look, a Pediatric Endocrinology Fellow at the University of Utah, supports the petition to prioritize patient choice in insulin selection. The commenter argues that individualized care is essential for managing type 1 diabetes, particularly during pregnancy, where specific insulin analogues have different safety and efficacy profiles.

A pediatric endocrinologist supports the petition to preserve access to insulin detemir, noting its clinical importance for children and patients with variable insulin sensitivity. The commenter argues that some patients cannot successfully transition to other basal insulins and emphasizes the need for therapeutic choice in individualized diabetes care.

Dr. David K. Tensmeyer, a physician and Type 1 diabetic, supports keeping insulin Detemir (Levemir) available as a flexible basal insulin option. He highlights its specific benefits for Type 1 diabetics and for managing insulin needs during the menstrual cycle.